Arriving in the landscape of obesity treatment, retatrutide is a unique strategy. Unlike many available medications, retatrutide functions as a dual agonist, simultaneously targeting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. This concurrent engagement promotes various advantageous effects, like